EUVIMEDEUVIMED entdecken
Open Access

Genetic Variations in TP53, RB1 , and PTEN in a Selected Sample of Slovak Patients With Metastatic Castration-resistant Prostate Cancer

Klaudia Hives Holeckova, Mark Hives, Marian Grendar, Henrieta Blahusiak Drobkova, Jan Kliment

In Vivo · 2024

DOI: 10.21873/invivo.13737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Klaudia Hives Holeckova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Comenius University in Bratislava, Martin, Slovakia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, PTEN Phosphohydrolase, Retinoblastoma Binding Proteins, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: This report aimed to present identified variants with pathogenic potential in three genes - TP53, PTEN, and RB1 - in a selected sample of patients with metastatic castration-resistant prostate cancer (mCRPC) with or without the presence of circulating tumor cells (CTCs) and splice variant AR-V7. MATERIALS AND METHODS: Next generation sequencing was performed on an Illumina platform to analyse the genetic profiles of 50 patients with mCRPC. Identified variants were validated using the Integrative Genomic Viewer, and the correlation between these variants and the presence of CTC/AR-V7 was subjected to statistical analysis. RESULTS: The study revealed a total of 15 genetic alterations in the three examined genes. The presence of rs1042522 (TP53) in mCRPC patients was associated with a significantly reduced likelihood of AR-V7 occurrence (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPTEN PhosphohydrolaseRetinoblastoma Binding ProteinsTumor Suppressor Protein p53Ubiquitin-Protein LigasesHumansMaleAgedMiddle AgedGenetic VariationSlovakiaProstate-Specific AntigenBiomarkers, TumorHigh-Throughput Nucleotide SequencingNeoplasm MetastasisMutationNeoplastic Cells, CirculatingAged, 80 and overReceptors, Androgen

Stichwörter der Autor:innen

ARV-7CTCNGSProstate cancertumour-suppressor genes

Substanzen

PTEN PhosphohydrolaseRB1 protein, humanRetinoblastoma Binding ProteinsTumor Suppressor Protein p53PTEN protein, humanUbiquitin-Protein LigasesTP53 protein, humanProstate-Specific AntigenBiomarkers, TumorReceptors, Androgen

Autor:innen und Institutionen

  • Department of Urology, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Comenius University in Bratislava, Martin, Slovakia.
  • Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
  • Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia.
  • Department of Urology, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Comenius University in Bratislava, Martin, Slovakia; jan.kliment@uniba.sk.

Zitieren

APA

Holeckova, K. H., Hives, M., Grendar, M., Drobkova, H. B., & Kliment, J. (2024). Genetic Variations in TP53, RB1 , and PTEN in a Selected Sample of Slovak Patients With Metastatic Castration-resistant Prostate Cancer. In Vivo. https://doi.org/10.21873/invivo.13737

Vancouver

Holeckova KH, Hives M, Grendar M, Drobkova HB, Kliment J. Genetic Variations in TP53, RB1 , and PTEN in a Selected Sample of Slovak Patients With Metastatic Castration-resistant Prostate Cancer. In Vivo. 2024. doi:10.21873/invivo.13737

BibTeX
@article{Holeckova2024,
  author = {Holeckova, Klaudia Hives and Hives, Mark and Grendar, Marian and Drobkova, Henrieta Blahusiak and Kliment, Jan},
  title = {Genetic Variations in TP53, RB1 , and PTEN in a Selected Sample of Slovak Patients With Metastatic Castration-resistant Prostate Cancer},
  journal = {In Vivo},
  year = {2024},
  doi = {10.21873/invivo.13737}
}
Kostenlos starten →